Indoco Remedies Limited (NSE:INDOCO)
210.36
-5.35 (-2.48%)
Jan 23, 2026, 3:29 PM IST
Indoco Remedies Employees
Indoco Remedies had 6,000 employees as of September 30, 2025. The number of employees did not change compared to the same quarter last year.
Employees
6,000
Change
n/a
Growth
n/a
Revenue / Employee
2.88M INR
Profits / Employee
-184.18K INR
Market Cap
19.90B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 6,000 | 0 | - |
| Jun 30, 2025 | 6,000 | 0 | - |
| Mar 31, 2025 | 6,051 | 122 | 2.06% |
| Dec 31, 2024 | 6,000 | 0 | - |
| Sep 30, 2024 | 6,000 | 0 | - |
| Jun 30, 2024 | 6,000 | 0 | - |
| Mar 31, 2024 | 5,929 | -169 | -2.77% |
| Dec 31, 2023 | 6,000 | 0 | - |
| Sep 30, 2023 | 6,000 | -1,000 | -14.29% |
| Jun 30, 2023 | 6,000 | -1,000 | -14.29% |
| Mar 31, 2023 | 6,098 | 171 | 2.89% |
| Dec 31, 2022 | 6,000 | 0 | - |
| Sep 30, 2022 | 7,000 | 1,000 | 16.67% |
| Jun 30, 2022 | 7,000 | 1,000 | 16.67% |
| Mar 31, 2022 | 5,927 | -154 | -2.53% |
| Dec 31, 2021 | 6,000 | 500 | 9.09% |
| Sep 30, 2021 | 6,000 | 500 | 9.09% |
| Jun 30, 2021 | 6,000 | 500 | 9.09% |
| Mar 31, 2021 | 6,081 | 221 | 3.77% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Solara Active Pharma Sciences | 1,775 |
| Innova Captab | 1,600 |
| Sigachi Industries | 1,507 |
| Jagsonpal Pharmaceuticals | 1,399 |
| Windlas Biotech | 1,346 |
| RPG Life Sciences | 1,331 |
| Ind-Swift Laboratories | 1,246 |
| Orchid Pharma | 736 |
Indoco Remedies News
- 2 months ago - Indoco Remedies Ltd (BOM:532612) Q2 2026 Earnings Call Highlights: Revenue Growth and Strategic ... - GuruFocus
- 2 months ago - Q2 2026 Indoco Remedies Ltd Earnings Call Transcript - GuruFocus
- 4 months ago - Indoco Remedies’ Patalganga API facility clears USFDA inspection with zero observations - Business Upturn
- 5 months ago - Why are Indoco Remedies shares up 2% today? Explained - Business Upturn
- 5 months ago - Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market - Business Upturn
- 6 months ago - Indoco Remedies signs Sale and Leaseback Agreemen for Waluj facility assets - Business Upturn
- 6 months ago - Indoco Remedies Q1 Results: Revenue flat at Rs 42 crore, Net loss of Rs 3.6 crore - Business Upturn
- 6 months ago - Indoco Remedies receives EU GMP certification for sterile drug facility in Goa - Business Upturn